Neostrata Problem Dry Skin Cream 100g

NeoStrata

Cosmetic skincare – targeted body treatment

Keratolytic AHA/PHA cream for severely dry, rough and hyperkeratotic skin

Marketed and regulated as a cosmetic/dermocosmetic product in relevant territories and not as a medicinal product or medical device.
Ingredient labelling (INCI) and claims are published on official NeoStrata pages and authorised retailers, consistent with cosmetic regulatory requirements in the UK/EU markets.

Marketed and regulated as a cosmetic/dermocosmetic product in relevant territories and not as a medicinal product or medical device.
Ingredient labelling (INCI) and claims are published on official NeoStrata pages and authorised retailers, consistent with cosmetic regulatory requirements in the UK/EU markets.

Keratolytic AHA/PHA cream for severely dry, rough and hyperkeratotic skin

Description

Neostrata Problem Dry Skin Cream 100g is a rich, dermatologist-developed AHA/PHA body cream formulated for severely dry, rough and thickened skin, particularly on areas such as knees, elbows and heels. The formula contains a high 20% Hydroxy Acid blend (AHA/PHA) together with Maltobionic Acid and Pro-Vitamin E to exfoliate and hydrate hyperkeratotic skin. The highly emollient base with beeswax and skin-conditioning oils helps to instantly reduce skin roughness on contact. NeoStrata state that significant improvement in heavily calloused skin can be seen in as little as three weeks of once-daily use. The product is fragrance-free and has an approximate pH of 3.6.

Bnefits

Formulated with a 20% Hydroxy Acid blend (AHA/PHA) to exfoliate and smooth severely dry, rough and thickened skin.
Targets problem areas such as knees, elbows and heels and is suitable for thickened, calloused skin.
Highly emollient vehicle (beeswax and skin-conditioning oils) reduces roughness on contact and improves spreadability.
Contains Maltobionic Acid and Pro-Vitamin E for added hydration and antioxidant support.
Fragrance-free formulation with amphoteric buffering to help reduce irritation risk compared with similarly high-strength AHA products.
Clinically reported improvement in heavily calloused skin within approximately 3 weeks of daily use (per manufacturer/retailer claims).

Indications

Severely dry, rough and thickened skin (hyperkeratosis) unresponsive to conventional moisturisers.
Heavily calloused areas such as knees, elbows and heels requiring intensive exfoliation and moisturisation.
Adjunctive cosmetic care to help soften psoriasis plaques and rough, scaly skin on non-facial body sites as part of a skincare regimen.

Composition

Active/functional actives: 20% Hydroxy Acid blend (combination of AHAs and PHAs) including Glycolic Acid, Lactic Acid, Mandelic Acid and Gluconolactone; Maltobionic Acid.
Skin-conditioning and emollient ingredients: Petrolatum, Mineral Oil, Cera Alba (Beeswax), Cetyl Alcohol, Stearyl Alcohol, Caprylic/Capric Triglyceride, Dimethicone.
Antioxidant: Pro-Vitamin E (Tocopheryl Acetate).
Other ingredients (INCI as published by NeoStrata / authorised retailers): Aqua (Water), Propylene Glycol, Petrolatum, Mineral Oil, Glycolic Acid, Lactic Acid, Mandelic Acid, Gluconolactone, Stearyl Alcohol, Cera Alba (Beeswax), PEG-40 Stearate, Sorbitan Stearate, Arginine, Ammonium Hydroxide, Maltobionic Acid, Cetyl Alcohol, Dimethicone, Tocopheryl Acetate, Magnesium Aluminium Silicate, Xanthan Gum, Disodium EDTA, Sodium Bisulfite, Methylparaben, Propylparaben, CI 19140, CI 17200.

Formulation

Rich, emollient cream formulation (wash-off not intended) for localised body application.
High-strength keratolytic formula (20% AHA/PHA) with amphoteric buffering (pH ~3.6) to balance efficacy and tolerability.
Fragrance-free, dermatologist-developed targeted treatment for hyperkeratotic skin sites.

Packaging

Supplied as a 100 g (3.4 fl oz) tube (branded NeoStrata tube with flip cap) and sold as a single retail unit.
Outer carton included where sold through authorised retailers; full carton artwork and batch labelling present in retail packaging.

Usage

Apply to affected areas once daily (some sources report once- or twice-daily use depending on tolerance; manufacturer guidance and retailer listings typically recommend once daily for problem dry skin).
For initial intensive treatment, follow product guidance; significant improvement has been reported after approximately 3 weeks of daily use.
Avoid application to broken, inflamed or eczema-affected skin unless advised by a clinician.
Because of the high AHA content, avoid excessive sun exposure on treated areas and use broad-spectrum sunscreen on exposed skin during treatment and for one week after discontinuation.
If irritation occurs, reduce frequency of application or discontinue and consult a skincare professional.

Contraindications

Not publicly listed as formal medical contraindications (cosmetic product).
General caution: do not use if hypersensitive to any ingredient in the INCI list (e.g. AHAs, beeswax, parabens or colourants).
Avoid use on broken or acutely inflamed skin; seek professional advice for use on sensitive areas or in patients with active dermatological disease.

Adverse Effects

Not published as a medicinal adverse-event table; potential reactions consistent with high-strength AHA/PHA products include stinging, burning, transient redness, peeling and increased sun sensitivity in susceptible individuals.
Allergic contact dermatitis or irritation may occur in sensitive persons; discontinue use if severe irritation develops.

Storage Conditions

Not specifically detailed in public retail listings; follow general cosmetic storage: store in original packaging, in a cool, dry place away from direct sunlight and excessive heat, and keep out of reach of children.

Duration

Not strictly defined; labelled and marketed for ongoing targeted use on problem areas. Manufacturer/retailer literature cites measurable improvement in heavy callus within approximately 3 weeks of once-daily use.

Onset

Significant improvement in heavily calloused skin has been demonstrated in as little as 3 weeks of once-daily use (manufacturer/retailer claim); no more precise onset timing for general use is published.